CD163 and COVID-19: The clinical significance of HO-1 in COVID-19 was not clear, so we investigated whether or not evaluating the degree of oxidative stress in COVID-19 by measuring serum HO-1 levels could be useful in predicting disease severity and treatment outcomes, and we compared these findings with the performance of another M2 biomarker, sCD163 [17–21].